Last reviewed · How we verify
NCT03782168
Plasma Concentration of Biological Markers in Placental Abruption
trial testing There is no other intervention, only clinical treatment. in Abruptio Placentae in 1 participant. Terminated before completion.
31 January 2019
Quick facts
| Lead sponsor | University of Arkansas |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 31 January 2019 |
| Primary completion | 31 January 2019 |
| Estimated completion | 1 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- There is no other intervention, only clinical treatment. — full drug profile →
Conditions studied
- Abruptio Placentae — all drugs for Abruptio Placentae →
Sponsor
University of Arkansas
Who can join
Adults 18 to 45, female only, with Abruptio Placentae. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers (specifically; placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1), vascular endothelial growth factor (VEGF), soluble endoglin (sEng)). Secondary outcomes if will examine the correlation between placental micro-particles, biomarkers, and extent of placental abruption.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03782168
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of There is no other intervention, only clinical treatment.
Trials testing the same drug.
- NCT04525534 — Plasma Concentration of Biological Markers in Placenta Accreta Spectrum · terminated
- NCT04422600 — Fetal Exposure to Cannabinoids: Exposure, Methylation and Neurodevelopmental Effects · completed
- NCT04302415 — Metabolomics Explores Biomarkers for Metastatic Breast Cancer · unknown
Other University of Arkansas trials
Trials by the same sponsor.
- NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
- NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients · NA · not yet recruiting
- NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
- NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
- NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03782168 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
- Last refreshed: 3 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03782168.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing